# Zachary R Mccaw

List of Publications by Year
in descending order



| 54 | 1,187 | 686830 13 | 433756 31 |
|---|---|---|---|
| papers | citations | h-index | g-index |

| 59 | 59 | 59 | 2246 |
|---|---|---|---|
| all docs | docs citations | times ranked | citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Leveraging a Surrogate Outcome to Improve Inference on a Partially Missing Target Outcome. Biometrics, 2023, 79, 1472-1484. | 0.8 | 1 |
| 2 | Questions About a Risk Prediction Model of Mortality After Esophagectomy for Cancer. JAMA Surgery, 2022, 157, 279. | 2.2 | 0 |
| 3 | DeepNull models non-linear covariate effects to improve phenotypic prediction and association power. Nature Communications, 2022, 13, 241. | 5.8 | 17 |
| 4 | Pitfall in the Design and Analysis of Comparative Oncology Trials With a Time-to-Event Endpoint and Recommendations. JNCI Cancer Spectrum, 2022, 6, . | 1.4 | 5 |
| 5 | Genome-wide association study of primary dysmenorrhea in the Taiwan Biobank validates associations near the NGF and IL1 gene loci. Journal of Human Genetics, 2022, , . | 1.1 | 0 |
| 6 | Practical Recommendations on Quantifying and Interpreting Treatment Effects in the Presence of Terminal Competing Risks. JAMA Cardiology, 2022, 7, 450. | 3.0 | 17 |
| 7 | Fitting Gaussian mixture models on incomplete data. BMC Bioinformatics, 2022, 23, . | 1.2 | 2 |
| 8 | Sample size calculation for randomized selection trials with a timeâ€toâ€event endpoint and a margin of practical equivalence. Statistics in Medicine, 2022, 41, 4022-4033. | 0.8 | 3 |
| 9 | Quantifying Treatment Effects in Trials with Multiple Event-Time Outcomes. , 2022, 1, . | | 10 |
| 10 | Transparency in reporting of phase 3 cancer clinical trial results. Acta OncolÃ³gica, 2021, 60, 191-194. | 0.8 | 3 |
| 11 | Re: Karim Fizazi, Charles G. Drake, Tomasz M. Beer, et al. Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.07.032. European Urology, 2021, 79, e10-e11. | 0.9 | 2 |
| 12 | Survival Analysis of Treatment Efficacy in Comparative Coronavirus Disease 2019 Studies. Clinical Infectious Diseases, 2021, 72, e887-e889. | 2.9 | 4 |
| 13 | Letter by McCaw et al Regarding Article, â€œThe COMPASS Trial: Net Clinical Benefit of Low-Dose Rivaroxaban Plus Aspirin as Compared With Aspirin in Patients With Chronic Vascular Diseaseâ€. Circulation, 2021, 143, e1-e2. | 1.6 | 4 |
| 14 | Olaparib in Metastatic Castration-Resistant Prostate Cancer. New England Journal of Medicine, 2021, 384, 1174-1176. | 13.9 | 1 |
| 15 | Quantifying the Long-term Survival Benefit of Pembrolizumab for Patients With Advanced Gastric Cancer. JAMA Oncology, 2021, 7, 632. | 3.4 | 0 |
| 16 | Quantifying the Effect of Lower vs Higher Positive End-Expiratory Pressure on Ventilator-Free Survival in ICU Patients. JAMA - Journal of the American Medical Association, 2021, 325, 1566. | 3.8 | 0 |
| 17 | Neoadjuvant chemotherapy in bladder cancer: Clinical benefit observed in prospective trials computed with restricted mean survival times. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 435.e17-435.e22. | 0.8 | 2 |
| 18 | Large-scale machine-learning-based phenotyping significantly improves genomic discovery for optic nerve head morphology. American Journal of Human Genetics, 2021, 108, 1217-1230. | 2.6 | 35 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Multitrait GWAS to connect disease variants and biological mechanisms. PLoS Genetics, 2021, 17, e1009713. | 1.5 | 16 |
| 20 | Choosing clinically interpretable summary measures and robust analytic procedures for quantifying the treatment difference in comparative clinical studies. Statistics in Medicine, 2021, 40, 6235-6242. | 0.8 | 5 |
| 21 | Operating characteristics of the rankâ€based inverse normal transformation for quantitative trait analysis in genomeâ€wide association studies. Biometrics, 2020, 76, 1262-1272. | 0.8 | 120 |
| 22 | Interpreting the Benefit of Simvastatin-Ezetimibe in Patients 75 Years or Older. JAMA Cardiology, 2020, 5, 235. | 3.0 | 0 |
| 23 | Utility of Restricted Mean Survival Time Analysis for HeartÂFailure Clinical Trial Evaluation and Interpretation. JACC: Heart Failure, 2020, 8, 973-983. | 1.9 | 28 |
| 24 | Fulvestrant plus capivasertib for metastatic breast cancer. Lancet Oncology, The, 2020, 21, e233. | 5.1 | 4 |
| 25 | Analysis of Response Data for Assessing Treatment Effects in Comparative Clinical Studies. Annals of Internal Medicine, 2020, 173, 368-374. | 2.0 | 18 |
| 26 | How to Quantify and Interpret Treatment Effects in Comparative Clinical Studies of COVID-19. Annals of Internal Medicine, 2020, 173, 632-637. | 2.0 | 37 |
| 27 | Further clinical interpretation and implications of KEYNOTE-048 findings. Lancet, The, 2020, 396, 378-379. | 6.3 | 4 |
| 28 | Selecting appropriate endpoints for assessing treatment effects in comparative clinical studies for COVID-19. Contemporary Clinical Trials, 2020, 97, 106145. | 0.8 | 10 |
| 29 | Applying Evidence-Based Medicine to Shared Decision Making: Value of Restricted MeanSurvival Time. American Journal of Medicine, 2019, 132, 13-15. | 0.6 | 27 |
| 30 | Design of Noninferiority Trials for Hypofractionated vs Conventional Radiotherapy Among Patients With Cancer. JAMA Oncology, 2019, 5, 1508. | 3.4 | 0 |
| 31 | Analysis of Long-term Benefits of Intensive Blood Pressure Control. JAMA - Journal of the American Medical Association, 2019, 322, 169. | 3.8 | 0 |
| 32 | P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy After Percutaneous Coronary Intervention. JAMA - Journal of the American Medical Association, 2019, 322, 1607. | 3.8 | 0 |
| 33 | Using the Restricted Mean Survival Time Difference as an Alternative to the Hazard Ratio for Analyzing Clinical Cardiovascular Studies. Circulation, 2019, 140, 1366-1368. | 1.6 | 56 |
| 34 | A Shorter Regimen for Rifampin-Resistant Tuberculosis. New England Journal of Medicine, 2019, 381, e22. | 13.9 | 2 |
| 35 | Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura. New England Journal of Medicine, 2019, 380, e32. | 13.9 | 4 |
| 36 | Comment on â€œInterpreting Clinical Benefits of Neoadjuvant Chemoradiation With Gemcitabine Versus Upfront Surgery in Patients With Borderline Resectable Pancreatic Cancer (BRPC)â€. Annals of Surgery, 2019, 270, e48-e50. | 2.1 | 3 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Interpreting the Prognostic Value of Unrecognized Myocardial Infarction Among Older Adults. JAMA Cardiology, 2019, 4, 391. | 3.0 | 0 |
| 38 | Radical Surgery or Watchful Waiting in Prostate Cancer. New England Journal of Medicine, 2019, 380, 1083-1084. | 13.9 | 2 |
| 39 | Interpreting the Survival Benefit From Neoadjuvant Chemoradiotherapy Before Surgery for Locally Advanced Squamous Cell Carcinoma of the Esophagus. Journal of Clinical Oncology, 2019, 37, 1032-1033. | 0.8 | 5 |
| 40 | Palbociclib and Fulvestrant in Breast Cancer. New England Journal of Medicine, 2019, 380, 796-797. | 13.9 | 4 |
| 41 | Evaluating Treatment Effect of Transcatheter Interatrial Shunt Device Using Heart Failure Event Rates. JAMA Cardiology, 2019, 4, 299. | 3.0 | 1 |
| 42 | Quantifying the benefit of non-small-cell lung cancer immunotherapy. Lancet, The, 2019, 394, 1904. | 6.3 | 8 |
| 43 | Toll-like receptor 4-mediated respiratory syncytial virus disease and lung transcriptomics in differentially susceptible inbred mouse strains. Physiological Genomics, 2019, 51, 630-643. | 1.0 | 13 |
| 44 | Body Composition and Overall Survival in Patients With Nonmetastatic Breast Cancer. JAMA Oncology, 2019, 5, 114. | 3.4 | 0 |
| 45 | Trifluridine/tipiracil in metastatic gastric cancer. Lancet Oncology, The, 2019, 20, e8. | 5.1 | 2 |
| 46 | Trastuzumab Therapy for 9 Weeks vs 1 Year for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. JAMA Oncology, 2019, 5, 117. | 3.4 | 1 |
| 47 | Quantifying the Added Value of Low-Molecular-Weight Heparin to Intermittent Pneumatic Compression for Preventing Venous Thromboembolic Events Under the Risk-Benefit Perspective. JAMA Surgery, 2019, 154, 270. | 2.2 | 0 |
| 48 | Sex as a predictor of response to cancer immunotherapy. Lancet Oncology, The, 2018, 19, e377. | 5.1 | 2 |
| 49 | Effects of mannose-binding lectin on pulmonary gene expression and innate immune inflammatory response to ozone. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2016, 311, L280-L291. | 1.3 | 17 |
| 50 | Determinants of host susceptibility to murine respiratory syncytial virus (RSV) disease identify a role for the innate immunity scavenger receptor MARCO gene in human infants. EBioMedicine, 2016, 11, 73-84. | 2.7 | 24 |
| 51 | Genome-wide specificities of CRISPR-Cas Cpf1 nucleases in human cells. Nature Biotechnology, 2016, 34, 869-874. | 9.4 | 566 |
| 52 | Novel Roles for Notch3 and Notch4 Receptors in Gene Expression and Susceptibility to Ozone-Induced Lung Inflammation in Mice. Environmental Health Perspectives, 2015, 123, 799-805. | 2.8 | 21 |
| 53 | Coincidental loss of DOCK8 function in NLRP10-deficient and C3H/HeJ mice results in defective dendritic cell migration. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 3056-3061. | 3.3 | 66 |
| 54 | Genetic Factors Involved in Susceptibility to Lung Disease. , 2014, , 369-384. | | 0 |